SCRI-huCAR19v1 / Seattle Children's Hospital - LARVOL DELTA

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Phase classification: P1/2 ➔ P1

CAR T-Cell Therapy • Phase classification • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Seattle Children's Hospital; Trial completion date: Jun 2036 ➔ Jun 2038; Trial primary completion date: Jun 2021 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Brain Cancer • Ewing Sarcoma • Eye Cancer • Gastrointestinal Cancer • Germ Cell Tumors • Hepatoblastoma • Hepatology • Nephrology • Neuroblastoma • Neurofibrosarcoma • Oncology • Osteosarcoma • Pediatrics • Retinal Disorders • Retinoblastoma • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Wilms Tumor • CD19 • EGFR